Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

• Autores: J. Gómez Millán, María Dolores Toledo Serrano, Yolanda Lupiáñez Pérez, Antonio Rueda Domínguez, José Manuel Trigo Pérez, José Antonio Medina Carmona
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 4, 2013, págs. 321-326
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background This study analyzes the morbidity and the contribution of different causes of death to the outcome of patients with locally advanced head and- neck cancer after weekly cisplatin plus concomitant boost accelerated radiation treated in our center.

    Materials and methods Ninety-four patients with locally advanced head and neck carcinoma were included in this phase II trial consisting of concomitant boost radiation plus concurrent weekly cisplatin. The 43 patients treated in our centered with long-term follow-up were analyzed. Patients received radiotherapy with a concomitant boost scheme (1.8 Gy on days 1�40 and 1.5 Gy boost on days 25�40 with a total dose of 72 Gy) and concurrent cisplatin, 40 mg/m2 weekly, for the first 4 weeks.

    Results Most patients (93 %) received both radiation and complete chemotherapy according to protocol. Severe late toxicity presented were subcutaneous (5 %), larynx (2 %) and esophagous (5 %). Grade I�II late toxicity included mainly xerostomy (30 %), skin (16 %) and mucosal (16 %) toxicity. With a median follow-up of 95 months (9�135), the median overall survival and progression-free survival were 26 and 19 months, respectively (95 % CI 1�52; and 95 % CI 0�45); 60 % of the patients died because of head and neck cancer and 12 % of a second neoplasm, while 27 % of non-cancer patients died.

    Conclusions Patients with locoregionally advanced head and neck cancer treated with concomitant boost accelerated radiation plus chemotherapy show significant risks of mortality from causes other than disease progression.